Lyell Immunopharma, Inc. (LYEL)
| Market Cap | 324.11M +147.6% |
| Revenue (ttm) | 31,000 -52.3% |
| Net Income | -246.41M |
| EPS | -13.06 |
| Shares Out | 23.33M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 140,918 |
| Open | 14.24 |
| Previous Close | 14.26 |
| Day's Range | 13.24 - 14.40 |
| 52-Week Range | 9.11 - 45.00 |
| Beta | -0.06 |
| Analysts | Buy |
| Price Target | 37.17 (+167.6%) |
| Earnings Date | Aug 11, 2026 |
About LYEL
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual‑targeting CD19/CD20 CAR T‑cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy random... [Read more]
Financial Performance
In 2025, Lyell Immunopharma's revenue was $36,000, a decrease of -40.98% compared to the previous year's $61,000. Losses were -$274.45 million, -19.98% less than in 2024.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for LYEL stock is "Buy." The 12-month stock price target is $37.17, which is an increase of 167.60% from the latest price.
News
Lyell Immunopharma files to sell 1.1M shares of common stock for holders
17:16 EDT Lyell Immunopharma (LYEL) files to sell 1.1M shares of common stock for holders
Lyell Immunopharma Registration statement: Registration filing
Lyell Immunopharma filed a registration statement on July 13, 2026, providing details about a securities offering with the SEC.
AbCellera apponts Lynn Seely to board of directors
AbCellera (ABCL) announced the appointment of Lynn Seely, M.D., to its Board of Directors as an independent director. Dr. Seely currently serves as president and CEO of Lyell Immunopharma (LYEL).
Lyell Immunopharma Transcript: H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
Two pivotal cell therapy programs are advancing, with LYL273 showing strong response rates and safety improvements in metastatic colorectal cancer and ronde-cel leading in large B-cell lymphoma. Key data updates and a BLA submission are expected within the next year, positioning both products for commercial launch.
Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
SOUTH SAN FRANCISCO, Calif., June 25, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor ...
Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress
More than 100 patients treated with ronde-cel in 2L and 3L+ LBCL, with a manufacturing success rate of 97% No Grade ≥ 3 CRS and low rates of Grade ≥ 3 ICANS, supporting outpatient administration Trans...
Lyell Immunopharma Transcript: AGM 2026
The meeting covered director elections, auditor ratification, and executive compensation, all of which were approved by shareholders. No questions were raised, and voting results will be reported on Form 8-K within four business days.
Lyell Immunopharma Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Major data updates for dual-targeting CAR T in lymphoma are expected in the second half, with pivotal data and BLA submission targeted for 2027. The colorectal cancer CAR T program shows improved safety and potential for expansion. Strong physician enthusiasm and a solid cash runway support ongoing clinical progress.
Lyell Immunopharma provides update on safety profile of LYL273
Lyell Immunopharma (LYEL) provided an update on the safety profile of LYL273 in its ongoing U.S. Phase 1 clinical trial in patients with relapsed or refractory metastatic colorectal cancer, and…
Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion
SOUTH SAN FRANCISCO, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor ...
Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress
SOUTH SAN FRANCISCO, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor ...
Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026
SOUTH SAN FRANCISCO, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor ...
Lyell Immunopharma Transcript: Stifel 2026 Targeted Oncology Virtual Forum
The company is advancing next-generation cell therapies with strong clinical data for ronde-cel in lymphoma and a novel dual CAR for colorectal cancer. Regulatory and manufacturing strategies are robust, with pivotal data and major updates expected soon. Cash reserves support operations through key milestones.
Lyell Immunopharma Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference
Ronde-cel leads the CD19/CD20 CAR T-cell space with strong efficacy, safety, and manufacturing readiness, outpacing competitors and targeting a large third-line lymphoma market. The colorectal cancer program shows promising, durable responses. Key pivotal data updates and regulatory milestones are expected this year and next.
Lyell Immunopharma Announces Participation in May Investor Conferences
SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (...
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026
PiNACLE pivotal clinical trial evaluating ronde-cel in patients with LBCL in third- or later-line setting on track to report additional data in second half of 2026, with pivotal data expected mid-2027...
Lyell Immunopharma Quarterly report: Q1 2026
Lyell Immunopharma has published its Q1 2026 quarterly earnings report on May 6, 2026.
Lyell Immunopharma Earnings release: Q1 2026
Lyell Immunopharma released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Lyell Immunopharma initiated with an Outperform at Baird on ronde-cel potential
As previously reported, Baird initiated coverage of Lyell Immunopharma (LYEL) with an Outperform rating and $49 price target Lyell’s pipeline is headlined by ronde-cel, for which a pair of pivotal…
Lyell Immunopharma initiated with an Outperform at Baird
Baird initiated coverage of Lyell Immunopharma (LYEL) with an Outperform rating and $49 price target
Lyell Immunopharma Proxy statement: Proxy filing
Lyell Immunopharma filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Lyell Immunopharma Proxy statement: Proxy filing
Lyell Immunopharma filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Lyell Immunopharma Transcript: 25th Annual Needham Virtual Healthcare Conference
The company is advancing next-generation CAR T-cell therapies, with ronde-cel showing high response rates and a favorable safety profile in pivotal trials. Manufacturing is fully in-house, and commercial launch is targeted for next year. LYL273 for solid tumors is also progressing, with promising early data and upcoming disclosures.
Lyell Immunopharma Stock (LYEL) Slides Despite Praise from a Top Wall Street Analyst
Lyell Immunopharma stock was down despite praise from a top Wall Street analyst on Friday.
Lyell Immunopharma initiated with a Buy at Needham
Needham initiated coverage of Lyell Immunopharma (LYEL) with a Buy rating and $44 price target The firm says the company’s ronde-cel is in the “pole position” for second-line diffuse large…